A randomized, double-blind, placebo-controlled pilot study of naltrexone to counteract antipsychotic-associated weight gain: proof of concept.

Abstract

Patients with schizophrenia experience higher rates of obesity as well as related morbidity and mortality than the general population does. Women with schizophrenia are at particular risk for antipsychotic-associated weight gain, obesity, and related medical disorders such as diabetes and cardiovascular disease. Given preclinical studies revealing the role of the endogenous opioid systems in human appetite and the potential of antipsychotic medications to interfere with this system, we hypothesized that opioid antagonists may be beneficial in arresting antipsychotic-associated weight gain and promoting further weight loss in women with schizophrenia. In the present study, 24 overweight women with a diagnosis of schizophrenia or schizoaffective disorder were randomized to placebo or naltrexone (NTX) 25 mg/d for 8 weeks. The primary outcome measure was a change in body weight from baseline. The patients in the NTX group had significant weight loss (-3.40 kg) compared with weight gain (+1.37 kg) in the patients in the placebo group. Mainly, nondiabetic subjects lost weight in the NTX arm. These data support the need to further investigate the role of D2 blockade in reducing food reward-based overeating. A larger study addressing the weaknesses of this pilot study is currently underway.

• Authors: Cenk Tek, Joseph Ratliff, Erin Reutenauer, Rohan Ganguli, Stephanie S O'Malley
• Journal: Journal of clinical psychopharmacology (J Clin Psychopharmacol) Vol. 34 Issue 5 Pg. 608-12 (Oct 2014) ISSN: 1533-712X [Electronic] United States
• PMID: 25102328 (Publication Type: Journal Article, Randomized Controlled Trial, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)

Chemical References

• Antipsychotic Agents
• Glycated Hemoglobin A
• Narcotic Antagonists
• Triglycerides
• hemoglobin A1c protein, human
• Naltrexone
• Cholesterol

Topics

• Adolescent
• Adult
• Aged
• Antipsychotic Agents (adverse effects)
• Cholesterol (blood)
• Double-Blind Method
• Female
• Glycated Hemoglobin (metabolism)
• Humans
• Middle Aged
• Naltrexone (therapeutic use)
• Narcotic Antagonists (therapeutic use)
• Pilot Projects
• Psychotic Disorders (drug therapy)
• Quality of Life
• Schizophrenia (blood, drug therapy, metabolism)
• Triglycerides (blood)
• Weight Gain (drug effects)
• Young Adult